American Society of Hematology

Figure 2.

$T-cell replete cord EFS stratified by clinical disease status. Two-year EFS was 79.6% for those in CR2, 67% for high risk CR1, 60.9% for those with primary refractory disease, and 46.5% for those with relapsed refractory disease. CR, complete remission.$

T-cell replete cord EFS stratified by clinical disease status. Two-year EFS was 79.6% for those in CR2, 67% for high risk CR1, 60.9% for those with primary refractory disease, and 46.5% for those with relapsed refractory disease. CR, complete remission.

This Feature Is Available To Subscribers Only